TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00748072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DDAVP
Description: 0.3 mcg/kg subcutaneous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline solution
Description: saline solution 1 ml subcutaneous
Study: NCT01931007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous Bone Marrow Aspirate Concentrate
Description: Autologous Bone marrow aspirate will be concentrated using Magellan Cell Separator and stem cell kit according to the Standard Operating Procedures is to be injected in the treatment knee. 5ml of treatment cells will be combined with 10 ml of previously separated platelet poor bone marrow plasma and used for injection under ultrasound guidance into one of the subject's painful knees.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile saline
Description: Bacteriostatic 0.9% sodium chloride, preservative free manufactured by Hospira will be injected into the control knee.
Study: NCT03125135

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MightySat RX Pulse Oximeter Sensor
Description: Noninvasive pulse oximeter finger sensor.
Study: NCT00947908

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hymenoptera venom
Description: Patients are treated with hymenoptera (bee or wasp) venom using subcutaneous injections. The initiation of immune therapy consists of a 52-hour-period in which patients are treated with increasing doses of hymenoptera venom. Afterwards, patients are treated with monthly subcutaneous injections with a fixed dose of hymenoptera venom. Blood will be collected directly before and 1 hour after initiation of immune therapy and after 12 months of immune therapy (directly before the next subcutaneous injection of hymenoptera venom).
Study: NCT04030091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 hours humulin R 100 IU/mL PIT
Description: PIT procedure: a venous catheter will be placed into one superficial vein at one arm, which will be connected to the insulin infusion pump and a glucose infusion pump via a three-way connector. Endothelial function will be measured by means of the Vendys 2 device. The blood glucose will be tested by means of a POCT meter and the CGM, and the PIT procedure will be started (10 pulses of 3 U of regular human insulin per hour). Blood glucose will be tested every 5 to 10 min and glucose infusion will be started once a drop in blood glucose is detected. Adjustment of glucose administration will be performed until a stable glucose value between 80 mg/dL to 160 mg/dL is reached. In parallel, endothelial function will be measured every 30 min. At the end of the PIT procedure, the venous catheter will be removed and the patient will be discharged until the next visit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 hours humulin R 100 IU/mL PIT
Description: As described for the Intervention 3 hours of pulsatile insulin infusion (PIT) with humulin R 100 IU/mL, the treatment duration is just one hour less.
Study: NCT00859872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risperidone oral solution
Description: risperidone oral solution (2-6mg/d) combination clonazepam (4-8mg/d) oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: haloperidol
Description: haloperidol IM injection (5-20mg/d)
Study: NCT03097107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saroglitazar Magnesium 1 mg
Description: Randomly assigned patients will receive saroglitazar magnesium 1 mg orally once each morning before breakfast for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saroglitazar Magnesium 2 mg
Description: Randomly assigned patients will receive saroglitazar magnesium 2 mg orally once each morning before breakfast for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saroglitazar Magnesium 4 mg
Description: Randomly assigned patients will receive saroglitazar magnesium 4 mg orally once each morning before breakfast for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Randomly assigned patients will receive placebo orally once each morning before breakfast for 12 weeks
Study: NCT03474757

Intervention type: OTHER
Intervention: Data Collection
Description: Data will be extracted from July 2009 to the last available database extraction

Intervention type: OTHER
Intervention: Data Collection
Description: Data will be extracted from July 2009 to the last available database extraction

Intervention type: OTHER
Intervention: Data Collection
Description: Data will be extracted from July 2009 to the last available database extraction
Study: NCT03184753

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OC-IgT cells
Description: Autologous human OC-IgT cells.
Study: NCT00905931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lycopene
Description: 30 mg oral, daily, for 21 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: starch
Study: NCT02821897

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Target-controlled intravenous anaesthesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total anaesthesia
Study: NCT02994810

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breastfeeding guidance
Description: Breastfeeding guidance
Study: NCT03500003

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute milk intake
Description: Food matrix: milk

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute Yogurt intake
Description: Food matrix: yogurt
Study: NCT00985894

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online Teledermatology Care
Description: Patients randomized to the intervention group will have their scheduled follow-up visits online via store and forward teledermatology.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional in Office Care
Description: Patients randomized to the control group will have their scheduled follow-up visits via conventional in office care.
Study: NCT01457716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Single inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Single inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Single inhalation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide
Description: Single inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol
Description: Single inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol
Description: Single inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol
Description: Single inhalation
Study: NCT00363168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: 0.3 mg/0.05 ml dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: 0.5 mg/0.05 ml dose
Study: NCT01056679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicine
Description: 50mg/m2 day 1 + 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTIC
Description: 375mg/m2 day 1 + 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: day 1 - 21

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: 6mg/m2 day 1 + 15
Study: NCT04790799

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment at the skin department at Gentofte Hospital
Description: Treatment in a hospital setting at Gentofte Hospital skin department
Study: NCT03851991

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arbidol
Description: oral
Study: NCT01457716

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol
Description: Single inhalation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Easyhaler
Description: Inhaler device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Easyhaler
Description: Inhaler device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Easyhaler
Description: Inhaler device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Turbohaler Forte
Description: Inhaler device
Study: NCT04263649

Intervention type: DEVICE
Intervention: Peripherally Inserted Central Catheter
Description: insertion of a Peripherally Inserted Central Catheter (PICC)
Study: NCT00919230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferrous sulphate tablets
Description: 200mg twice daily for four weeks
Study: NCT01503736

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ferric citrate
Description: 0g/day ferric citrate capsule, TID for 56 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ferric citrate
Description: 4g/day ferric citrate capsule, TID for 56 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ferric citrate
Description: 6 g/day ferric citrate capsule, TID for 56 days
Study: NCT02408302

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: comparison between 3 routes of administration of the drug Midazolam used for sedation for minor procedures in pediatric population. the routes are oral intranasal and buccal.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: comparison between 3 routes of administration of the drug Midazolam used for sedation for minor procedures in pediatric population. the routes are oral intranasal and buccal.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: comparison between 3 routes of administration of the drug Midazolam used for sedation for minor procedures in pediatric population. the routes are oral intranasal and buccal.
Study: NCT03411148

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weekly exercise sessions with physical therapist and psychologist
Description: Eight weekly sessions integrating techniques from physical therapy and cognitive behavioral therapy. At the start of each session participants play virtual reality games that target balance and functional gait and then discuss their balance confidence and activity avoidance behaviors with a behavioural counselor. Weekly homework assignments ask participants to report on thoughts causing them to avoid activities and to slowly engage in activities that present increasing levels of fear.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Home-based exercises
Description: Stretching and other exercises are safely taught by physical therapist and then practiced at home following a provided schedule. Participants receive periodic calls to discuss progress.
Study: NCT03851991

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: controle
Study: NCT01422902

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plasticity-based Cognitive Training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-plasticity-based Training
Description: Computer games
Study: NCT04518085

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medical hypnosis
Description: Single session 20 minutes hypnosis session originally developed and tested by Montgomery et al. (2007) in a similar setting. Delivered by an experienced clinical psychologist.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based Acceptance and Commitment Therapy (iACT)
Description: Access to an online platform developed to this study containing video clips and audio files with ACT consistent material

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness session
Description: Single session mindfulness session delivered by audio file

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual (TAU)
Description: Treatment as usual as part of post-surical care
Study: NCT01056536

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured intervention for the prevention of sexually transmitted infections (STI).
Description: The structured intervention will include information about the number of travelers engaging in new sexual relationships, the different types of STI and their prevalence in different countries and population groups. The intervention will last approximately 5 minutes. At the end of the structured intervention the subjects will be offered free condoms.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Free condoms
Description: Subjects will be proposed free condoms at the end of the pre-travel consultation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Free condoms
Description: Subjects will be proposed free condoms at the end of the pre-travel consultation.
Study: NCT04376671

Intervention type: DEVICE
Intervention: Electroencephalography
Description: The patients underwent EEG recordings according to previously published methods (Bonanni et al., 2008). . EEG recordings were analyzed with methods described in our previous work (Bonanni et al., 2008) by 2 experimenters unaware of the clinical conditions of the subjects. Briefly, quantitative EEGs (QEEGs) were recorded from 21 scalp derivations. Ag/AgCl disk scalp electrodes (19) were placed according to the international 10-20 system, EEG was recorded from Fp1, Fp2, Fz, F3, F4, F7, F8, Cz, C3, C4, Pz, P3, P4, T3, T 4, T5, T6, O1, and O2. Two additional electrodes were placed on A1 and A2. EEG activity was analyzed from single or multiple leads grouped to define the following scalp regions: anterior (Fz, Fp2, F7, Fp1, F3, F4, and F8), central (Cz, C3, and C4), posterior (Pz, P3, P4, O1, and O2), and temporal (T3, T4, T5, and T6).

Intervention type: DEVICE
Intervention: Electroencephalography
Description: The patients underwent EEG recordings according to previously published methods (Bonanni et al., 2008). . EEG recordings were analyzed with methods described in our previous work (Bonanni et al., 2008) by 2 experimenters unaware of the clinical conditions of the subjects. Briefly, quantitative EEGs (QEEGs) were recorded from 21 scalp derivations. Ag/AgCl disk scalp electrodes (19) were placed according to the international 10-20 system, EEG was recorded from Fp1, Fp2, Fz, F3, F4, F7, F8, Cz, C3, C4, Pz, P3, P4, T3, T 4, T5, T6, O1, and O2. Two additional electrodes were placed on A1 and A2. EEG activity was analyzed from single or multiple leads grouped to define the following scalp regions: anterior (Fz, Fp2, F7, Fp1, F3, F4, and F8), central (Cz, C3, and C4), posterior (Pz, P3, P4, O1, and O2), and temporal (T3, T4, T5, and T6).
Study: NCT02290418

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Roux-en-Y Gastric Bypass
Description: Laparoscopic Gastric Bypass performed with two anastomoses (gastro-enteral and entero- enteral), two limbs (Alimentary limb of length 150cm and Biliary limb of length 75-100cm) and sewing of mesenteric defect.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Omega-Loop Gastric Bypass
Description: Laparoscopic Gastric Bypass performed with single anastomosis (gastro-enteral) connecting a long gastric pouch to small bowel with Afferent limb of length 200cm.
Study: NCT00937196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo globuli
Description: placebo globuli administered together with verbal suggestions of a hypotensive drug effect

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Histaminum hydrochloricum globuli
Study: NCT02924870

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health education program
Description: 2 sessions, at 15 and 30 days after hospital discharge. The first session will consist of four stages:~* Basic formation: basic lung anatomy and physiology, COPD concept, importance of tobacco, diagnostic tests for COPD, and how COPD is treated.~* Care in COPD: diet, breathing exercises, physical exercise (walking, cycle, treadmill ...), lifestyle (clothing, hygiene, preening, exercise, rest, sexuality, social relations).~* Management of conventional treatment: inhalers, oxygen therapy and smoking cessation.~* Action Plan: the patient and the nurse will establish a target about the activities that the patient must perform as well as their frequency and duration, according to WHO guidelines.~Second session: changes from the previous session; compliance with the physical activity plan and the deviation causes; weaknesses of the patient; skills in the management of inhalers, oxygen, and breathing exercises; and a new physical activity plan.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional management
Description: Treatment and follow-up according to conventional clinical practice (GesEPOC guidelines), including recommendations on healthy habits and lifestyle.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional management
Description: Treatment and follow-up according to conventional clinical practice (GesEPOC guidelines), including recommendations on healthy habits and lifestyle.
Study: NCT05001048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine Hydrochloride
Description: Series of three incremental bolus injections to observe α1-adrenoreceptor mediated vasoconstriction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine Hydrochloride
Description: Series of three incremental bolus injections to observe α1-adrenoreceptor mediated vasoconstriction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine Hydrochloride
Description: Series of three incremental bolus injections to observe α1-adrenoreceptor mediated vasoconstriction.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold Pressor Test
Description: Standardized sympathetic stressor involving submersion of the hand in ice-cold water for 3-minutes, aiming to elicit endogenous neurotransmitter release and blood pressure increases.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold Pressor Test
Description: Standardized sympathetic stressor involving submersion of the hand in ice-cold water for 3-minutes, aiming to elicit endogenous neurotransmitter release and blood pressure increases.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold Pressor Test
Description: Standardized sympathetic stressor involving submersion of the hand in ice-cold water for 3-minutes, aiming to elicit endogenous neurotransmitter release and blood pressure increases.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isocapnic Acute Hypoxia
Description: During low altitude assessment, participants will be exposed to isocapnic hypoxia equivalent to 3,800m to assess responses to acute exposure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperoxia
Description: During high altitude assessments, participants will breathe an oxygen concentration comparable to their end-tidal values at low altitude for the assessment of the influences of acclimatization.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperoxia
Description: During high altitude assessments, participants will breathe an oxygen concentration comparable to their end-tidal values at low altitude for the assessment of the influences of acclimatization.
Study: NCT03658772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: grapiprant
Description: Cohort 1 will be treated for 1 week with oral grapiprant as a single agent, followed by 21-day combination treatment cycles of oral grapiprant in combination with IV pembrolizumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: grapiprant and pembrolizumab
Description: Cohort 2 will be administered 21-day combination treatment cycles of oral grapiprant in combination with IV pembrolizumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: grapiprant and pembrolizumab
Description: Cohort 2 will be administered 21-day combination treatment cycles of oral grapiprant in combination with IV pembrolizumab.
Study: NCT01311791

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Algisyl-LVR
Description: Algisyl-LVR™ device (implants) administered during a surgical procedure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard medical therapy
Description: as defined per protocol
Study: NCT00355719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir (Reyataz)
Description: Atazanavir (Reyataz): capsules 150 mg (2 capsules/24h)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir (Norvir)
Description: Ritonavir (Norvir): capsules 100 mg (1 capsule/24h)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine (Viramune)
Description: Nevirapine (Viramune): tablets 200 mg (1 tablet/12h\*)
Study: NCT06161961

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WRL TTP
Description: evaluation of functionality, degree of safety and reliability of the lower limb prosthesis prototype
Study: NCT03290326

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Alternating Current Stimulation (tACS)
Description: tACS will be applied at a frequency of 40Hz and targeting the area of maximal tracer uptake on amyloid PET imaging using an individualized multielectrode design to maximize the induced electrical current to the target region.
Study: NCT00843973

Intervention type: PROCEDURE
Intervention: iliac crest bone graft
Description: iliac crest bone graft procedure

Intervention type: PROCEDURE
Intervention: Reamer Irrigator Aspirator
Description: Reamer Irrigator Aspirator (RIA) Procedure
Study: NCT00988026

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minocycline vs Lymecycline
Description: Minocycline 100 mg OD per mouth for 8 weeks. Lymecycline 300 mg OD per mouth for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline vs Lymecycline
Description: Minocycline 100 mg OD per mouth for 8 weeks. Lymecycline 300 mg OD per mouth for 8 weeks.
Study: NCT03542760

Intervention type: DRUG
Intervention: Methylene Blue
Description: Administration of methylene blue as per the treating physician's diagnosis and the acute care facility's standard of care

Intervention type: DRUG
Intervention: Methylene Blue
Description: Administration of methylene blue as per the treating physician's diagnosis and the acute care facility's standard of care
Study: NCT02084797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V2R (Vasopressin 2 receptor)
Description: All ten subjects were used as their own controls in this double-blind, randomized controlled trial assessing the effect of the V2R on sweat sodium concentration via use of a V2R blocker (antagonist), stimulator (agonist), against a placebo (drug naive state).
Study: NCT03823027

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SiPore15™
Description: SiPore15™ is a taste- and odourless white powder, consisting of precisely engineered micrometre sized synthetic amorphous silicon dioxide. The device is made of pure silicon dioxide, SiO2, which has the CAS Number: 112926-00-8 and EC List number: 601-214-2.
Study: NCT05969691

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Validation of IDH1 mutations from the radiomics model
Description: During surgery, clinicians will select several typical target sites for puncture based on the preoperative model outputs. After surgery, the acquired tumour tissues will be subjected to histological diagnosis and pathological diagnosis by professional pathologists, and the results will be compared with the model output to verify its accuracy.